

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on
April 1, 2010
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.


Deborah Barragan

Attorney Docket No: 305J-895030US
Client Ref No.: SF98-C32-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

James Marks, et al.

Patent No. 7,244,826

Issued: July 17, 2007

For: INTERNALIZING ERBB2
ANTIBODIES

Examiner: Susan Ungar

Art Unit: 1642

REQUEST FOR CERTIFICATE OF
CORRECTION PURSUANT TO 37 CFR
§1.322(a)

Attention: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate

APR 7 2010

of Correction

Sir:

Pursuant to 37 CFR §1.322(a), Applicants submit a Certificate of Correction correcting errors made at the time of printing of the patent. The desired corrections are set forth on enclosed Form PTO 1050.

The errors to be corrected by the Certificate include corrections to the specification at columns 10, 14, and 16.

At column 10, line 4, the PTO erroneously included the term "mM" (millimolar) instead of the intended term "μM" (micromolar). The original filed application contains the typographical error "M". The correct resolution of this typographical error is "μM", as one of skill in the art would immediately recognize that antibodies exhibiting binding affinities in the mM (i.e., 1000 μM) range are of no practical value, i.e., they bind antigens extremely weakly (in this context, lower molarity values represent higher affinities). Support for this correction can be found in USPN 7,244,826 at, e.g., column 2, lines 53 – 57 and column 22 lines 52 –56; and in claims 3, 12, and 18. These

04/05/2010 EEKUBAY1 00000056 500893 7244826
01 FC:1811 100.00 DA

μM). Support for this correction can also be found in Example 1 and Table 2, where anti-c-erbB2 antibodies with binding affinities of 0.22×10^{-9} – 4.03×10^{-9} are described; and in Example 3, which describes experiments that were performed to increase the binding affinity of the C6.5 antibody for c-erbB2 to 1.3×10^{-11} .

At column 10, line 5, the term “mM” is a printing error and should be changed to “nM”, as it appears in the original filed application.


At column 14, line 61, the term “F1” should be changed to “F5”. Though the original filed application contains the typographical error “F1”, support for this correction can be found throughout the specification, as the invention is directed to F5 antibodies, not F1 antibodies.

At column 16, line 6, the term “Q Ξ ” should be changed to “Q β ”. The original filed application contains the typographical error “Q Ξ ”. The correct resolution to this error is “Q β ”, as one of skill in the art would immediately recognize that Q β -replicase can be used to amplify nucleic acids. Furthermore, there is no “Q Ξ ” replicase.

Please deduct \$100.00, pursuant to 37 CFR §1.20(a), from the undersigned’s Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

QUINE INTELLECTUAL PROPERTY LAW
GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
Tel: 510 337-7871
Fax: 510 337-7877

Respectfully submitted,



Christina Onufryk
Reg. No: 59,842